JP2009526770A - 転移性乳癌の治療 - Google Patents
転移性乳癌の治療 Download PDFInfo
- Publication number
- JP2009526770A JP2009526770A JP2008553685A JP2008553685A JP2009526770A JP 2009526770 A JP2009526770 A JP 2009526770A JP 2008553685 A JP2008553685 A JP 2008553685A JP 2008553685 A JP2008553685 A JP 2008553685A JP 2009526770 A JP2009526770 A JP 2009526770A
- Authority
- JP
- Japan
- Prior art keywords
- epcam
- treatment
- dose
- patients
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 163
- 206010055113 Breast cancer metastatic Diseases 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 102
- 238000012423 maintenance Methods 0.000 claims description 39
- 230000037396 body weight Effects 0.000 claims description 30
- 238000011068 loading method Methods 0.000 claims description 23
- 206010027476 Metastases Diseases 0.000 claims description 15
- 230000006641 stabilisation Effects 0.000 claims description 11
- 238000011105 stabilization Methods 0.000 claims description 11
- 230000007774 longterm Effects 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- 230000003442 weekly effect Effects 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 181
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 179
- 230000014509 gene expression Effects 0.000 description 73
- 230000004044 response Effects 0.000 description 65
- 238000004458 analytical method Methods 0.000 description 56
- 206010006187 Breast cancer Diseases 0.000 description 44
- 208000026310 Breast neoplasm Diseases 0.000 description 43
- 206010061818 Disease progression Diseases 0.000 description 43
- 230000005750 disease progression Effects 0.000 description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 230000003902 lesion Effects 0.000 description 41
- 201000010099 disease Diseases 0.000 description 40
- 238000012360 testing method Methods 0.000 description 30
- 229940079593 drug Drugs 0.000 description 27
- 238000012216 screening Methods 0.000 description 27
- 238000001802 infusion Methods 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 22
- 230000008901 benefit Effects 0.000 description 21
- 230000002411 adverse Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000036961 partial effect Effects 0.000 description 20
- 238000002591 computed tomography Methods 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 19
- 210000000481 breast Anatomy 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000005259 measurement Methods 0.000 description 14
- 238000001325 log-rank test Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 238000012552 review Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 229960000575 trastuzumab Drugs 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 5
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 5
- 238000007469 bone scintigraphy Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 238000010206 sensitivity analysis Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 229960004117 capecitabine Drugs 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 230000005584 early death Effects 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 238000005353 urine analysis Methods 0.000 description 4
- 206010061728 Bone lesion Diseases 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 208000030776 invasive breast carcinoma Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229940086322 navelbine Drugs 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- -1 capecitabine Chemical compound 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77242106P | 2006-02-09 | 2006-02-09 | |
| EP06002680 | 2006-02-09 | ||
| PCT/EP2007/001127 WO2007090670A1 (en) | 2006-02-09 | 2007-02-09 | Treatment of metastatic breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272352A Division JP2013067645A (ja) | 2006-02-09 | 2012-12-13 | 転移性乳癌の治療 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2009526770A true JP2009526770A (ja) | 2009-07-23 |
Family
ID=38110762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553685A Pending JP2009526770A (ja) | 2006-02-09 | 2007-02-09 | 転移性乳癌の治療 |
| JP2012272352A Pending JP2013067645A (ja) | 2006-02-09 | 2012-12-13 | 転移性乳癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272352A Pending JP2013067645A (ja) | 2006-02-09 | 2012-12-13 | 転移性乳癌の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7976842B2 (enExample) |
| EP (1) | EP1981539B1 (enExample) |
| JP (2) | JP2009526770A (enExample) |
| KR (1) | KR101296264B1 (enExample) |
| AU (1) | AU2007213920B2 (enExample) |
| CA (1) | CA2638040A1 (enExample) |
| IL (1) | IL192944A0 (enExample) |
| RU (1) | RU2434640C2 (enExample) |
| WO (1) | WO2007090670A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013067645A (ja) * | 2006-02-09 | 2013-04-18 | Amgen Research (Munich) Gmbh | 転移性乳癌の治療 |
| JP2024073594A (ja) * | 2011-05-16 | 2024-05-29 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| EP2589668A1 (en) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Rare cell analysis using sample splitting and DNA tags |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
| DE102006035617A1 (de) * | 2006-07-31 | 2008-02-21 | Siemens Ag | Automatische Bestimmung von Tumorlast |
| US9078888B2 (en) * | 2007-01-22 | 2015-07-14 | Gtx, Inc. | Nuclear receptor binding agents |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| JP5130999B2 (ja) * | 2008-03-31 | 2013-01-30 | 住友ベークライト株式会社 | 抗癌剤の有効性予測方法 |
| ES2620294T3 (es) | 2008-09-20 | 2017-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnóstico no invasivo de la aneuploidia fetal por secuenciación |
| WO2011091154A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of California | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |
| BR112013014076A2 (pt) * | 2010-12-06 | 2016-11-22 | Cure Cancer Worldwide Corp | métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer |
| FR2977674B1 (fr) * | 2011-07-06 | 2015-08-14 | Cisbio Bioassays | Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule |
| EP2748197A2 (en) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| US20130179184A1 (en) * | 2012-01-06 | 2013-07-11 | Katherine L. Hurst | Individualized Dosing Technique With Multiple Variables |
| WO2013142390A1 (en) * | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
| KR102643443B1 (ko) | 2012-11-13 | 2024-03-06 | 비온테크 에스이 | 클라우딘 발현 암 질환의 치료제 |
| US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2015065505A1 (en) * | 2013-10-29 | 2015-05-07 | Duke University | Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer |
| US10975164B2 (en) | 2018-02-26 | 2021-04-13 | Emory University | Antibodies useful for detection of human carcinoma antigen |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009097A1 (en) * | 2003-03-31 | 2005-01-13 | Better Marc D. | Human engineered antibodies to Ep-CAM |
| WO2005080428A2 (en) * | 2004-02-13 | 2005-09-01 | Micromet Ag | Anti-epcam immunoglobulins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2194528C2 (ru) * | 1996-05-31 | 2002-12-20 | Дзе Скриппс Рисерч Инститьют | Способы и композиции, используемые для ингибирования ангиогенеза |
| RU2188025C2 (ru) * | 2000-07-19 | 2002-08-27 | Ростовский научно-исследовательский онкологический институт | Способ лечения рака молочной железы |
| WO2007090670A1 (en) * | 2006-02-09 | 2007-08-16 | Micromet Ag | Treatment of metastatic breast cancer |
| PT2520590T (pt) * | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
-
2007
- 2007-02-09 WO PCT/EP2007/001127 patent/WO2007090670A1/en not_active Ceased
- 2007-02-09 JP JP2008553685A patent/JP2009526770A/ja active Pending
- 2007-02-09 CA CA002638040A patent/CA2638040A1/en not_active Abandoned
- 2007-02-09 KR KR1020087020271A patent/KR101296264B1/ko not_active Expired - Fee Related
- 2007-02-09 US US12/162,102 patent/US7976842B2/en not_active Expired - Fee Related
- 2007-02-09 EP EP07703377.7A patent/EP1981539B1/en active Active
- 2007-02-09 AU AU2007213920A patent/AU2007213920B2/en not_active Ceased
- 2007-02-09 RU RU2008130963/15A patent/RU2434640C2/ru not_active IP Right Cessation
-
2008
- 2008-07-22 IL IL192944A patent/IL192944A0/en unknown
-
2011
- 2011-07-11 US US13/180,093 patent/US8337843B2/en not_active Expired - Fee Related
-
2012
- 2012-12-13 JP JP2012272352A patent/JP2013067645A/ja active Pending
- 2012-12-19 US US13/719,866 patent/US8658172B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009097A1 (en) * | 2003-03-31 | 2005-01-13 | Better Marc D. | Human engineered antibodies to Ep-CAM |
| WO2005080428A2 (en) * | 2004-02-13 | 2005-09-01 | Micromet Ag | Anti-epcam immunoglobulins |
Non-Patent Citations (3)
| Title |
|---|
| JPN5008024647; ＰＲＡＮＧ， Ｎ．， ｅｔ ａｌ．: 'Ｃｅｌｌｕｌａｒ ａｎｄ ｃｏｍｐｌｅｍｅｎｔ-ｄｅｐｅｎｄｅｎｔ ｃｙｔｏｔｏｘｉｃｉｔｙ ｏｆ Ｅｐ-ＣＡＭ-ｓｐｅｃｉｆｉｃ ｍｏｎｏｃｌｏｎａｌ ａｎｔｉｂｏｄｙ ＭＴ２０１ ａｇａｉｎｓｔ' ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ Ｖｏｌ．９２， Ｎｏ．２, 20050131, ｐ．３４２-３４９ * |
| JPN5008024648; ＲＡＵＭ， Ｔ．， ｅｔ ａｌ．: 'Ａｎｔｉ-ｓｅｌｆ ａｎｔｉｂｏｄｉｅｓ ｓｅｌｅｃｔｅｄ ｆｒｏｍ ａ ｈｕｍａｎ ＩｇＤ ｈｅａｖｙ ｃｈａｉｎ ｒｅｐｅｒｔｏｉｒｅ： ａ ｎｏｖｅｌ ａｐｐｒｏａｃｈ ｔｏ ｇｅｎｅｒａｔｅ' ＣＡＮＣＥＲ ＩＭＭＵＮＯＬＯＧＹ ＡＮＤ ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖｏｌ．５０， Ｎｏ．３, 200105, ｐ．１４１-１５０ * |
| JPN5008024649; ＮＡＵＮＤＯＲＦ， Ｓ．， ｅｔ ａｌ．: 'ＩＮ ＶＩＴＲＯ ＡＮＤ ＩＮ ＶＩＶＯ ＡＣＴＩＶＩＴＹ ＯＦ ＭＴ２０１， Ａ ＦＵＬＬＹ ＨＵＭＡＮ ＭＯＮＯＣＬＯＮＡＬ ＡＮＴＩＢＯＤＹ ＦＯＲ ＰＡＮＣＡＲＣＩＮＯＭＡ ＴＲＥＡＴＭＥＮＴ' ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ Ｖｏｌ．１００， Ｎｏ．１, 2002, ｐ．１０１-１１０ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013067645A (ja) * | 2006-02-09 | 2013-04-18 | Amgen Research (Munich) Gmbh | 転移性乳癌の治療 |
| JP2024073594A (ja) * | 2011-05-16 | 2024-05-29 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| IL192944A0 (en) | 2009-02-11 |
| US20090304716A1 (en) | 2009-12-10 |
| EP1981539A1 (en) | 2008-10-22 |
| RU2434640C2 (ru) | 2011-11-27 |
| US20130177578A1 (en) | 2013-07-11 |
| EP1981539B1 (en) | 2014-07-23 |
| KR101296264B1 (ko) | 2013-08-14 |
| JP2013067645A (ja) | 2013-04-18 |
| RU2008130963A (ru) | 2010-03-20 |
| AU2007213920A1 (en) | 2007-08-16 |
| AU2007213920B2 (en) | 2013-08-29 |
| US20120009204A1 (en) | 2012-01-12 |
| WO2007090670A1 (en) | 2007-08-16 |
| US7976842B2 (en) | 2011-07-12 |
| US8337843B2 (en) | 2012-12-25 |
| KR20080091817A (ko) | 2008-10-14 |
| CA2638040A1 (en) | 2007-08-16 |
| US8658172B2 (en) | 2014-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526770A (ja) | 転移性乳癌の治療 | |
| US20250154274A1 (en) | Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment | |
| EP4205769A9 (en) | Cd8 imaging constructs and methods of use thereof | |
| US20220288199A1 (en) | Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers | |
| Pérez-García et al. | Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial | |
| US20180134803A1 (en) | Treatment of her2-positive breast cancer | |
| JP2019526613A (ja) | 癌のための併用療法 | |
| JP2024502243A (ja) | 無細胞ｄｎａ断片化を用いた肺癌の検出 | |
| CN110208535A (zh) | 基于caix分级的癌症治疗 | |
| Higashi et al. | P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer | |
| TW202043273A (zh) | 用於晚期實性瘤癌症之治療性ｒｎａ | |
| Gauthier et al. | Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL | |
| JP6948080B2 (ja) | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 | |
| WO2014028221A1 (en) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug | |
| HK1123987A (en) | Treatment of metastatic breast cancer | |
| HK1123987B (en) | Treatment of metastatic breast cancer | |
| Wirth et al. | PD-1 Blockade in Anaplastic Thyroid Carcinoma | |
| Sparano et al. | Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma | |
| EP4475885A1 (en) | Combination therapy for use in treatment of non-small cell lung cancer | |
| Andrés et al. | Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study | |
| Schmid et al. | Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study | |
| CN118900700A (zh) | 用于治疗非小细胞肺癌的联合疗法 | |
| DIERAS et al. | CONTACT DETAILS PROTOCOL N: UC-0105/1815 | |
| Lopez et al. | Clinical safety and effi cacy of pembrolizumab in patients with malignant pleural mesothelioma: preliminary results from the phase 1b, non-randomised, open-label KEYNOTE-028 trial | |
| CN102961747A (zh) | 转移性乳腺癌的治疗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120123 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120411 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120723 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120813 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20120921 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130327 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130402 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130426 |